Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V. Freyer G, et al. Among authors: bleiberg h. Br J Cancer. 2000 Aug;83(4):431-7. doi: 10.1054/bjoc.2000.1303. Br J Cancer. 2000. PMID: 10945486 Free PMC article. Clinical Trial.
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E. Bensmaïne MA, et al. Among authors: bleiberg h. Br J Cancer. 2001 Aug 17;85(4):509-17. doi: 10.1054/bjoc.2001.1953. Br J Cancer. 2001. PMID: 11506488 Free PMC article. Clinical Trial.
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H. Van Cutsem E, et al. Among authors: bleiberg h. Eur J Cancer. 1999 Jan;35(1):54-9. doi: 10.1016/s0959-8049(98)00353-0. Eur J Cancer. 1999. PMID: 10211088 Free article. Clinical Trial.
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
Rougier P, van Pottelsberghe C, Kok T, Paillot B, Wagener T, De Greve J, Fabri MC, Gerard B, Van Glabbeke M, Bleiberg H. Rougier P, et al. Among authors: bleiberg h. Eur J Cancer. 1996 Jul;32A(8):1432-3. doi: 10.1016/0959-8049(96)00088-3. Eur J Cancer. 1996. PMID: 8869111 Clinical Trial.
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
Bensmaïne, de Gramont A, Brienza S, Marty M, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Bleuzen P, Simon J, Cvitkovic E. Bensmaïne, et al. Among authors: bleiberg h. Eur J Cancer. 2000 Dec;36(18):2335-43. doi: 10.1016/s0959-8049(00)00305-1. Eur J Cancer. 2000. PMID: 11094307 Clinical Trial.
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group; Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, et al. Among authors: bleiberg h. Eur J Cancer. 2013 May;49(7):1565-77. doi: 10.1016/j.ejca.2012.12.016. Epub 2013 Jan 24. Eur J Cancer. 2013. PMID: 23352439 Review.
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H. Van Cutsem E, et al. Among authors: bleiberg h. Br J Cancer. 2005 Mar 28;92(6):1055-62. doi: 10.1038/sj.bjc.6602462. Br J Cancer. 2005. PMID: 15756271 Free PMC article. Clinical Trial.
187 results